PharmCAT.NET

Biostatistics, pharmacokinetics and clinical trials.

  • Home page
  • Blog
  • Contacts
  • Agreement & Confidentiality

IBM SPSS Extension: R Project PowerTOST library

Posted on December 31, 2018December 31, 2018 by frozencat

IBM SPSS Extension PowerTOST R Project library. Syntax command: POWERTOST.

Version: 1.0.0

Functions:

  • power.TOST
  • sampleN.TOST
  • CVfromCI

Дизайны:

  • parallel
  • 2×2
  • 2x2x4

Скачать/Download

GitHUB: https://github.com/PharmCat/SPSSPowerTOST

Categories: Blog, SPSS

Post navigation

Next Post:

Recent Posts

  • IBM SPSS + R Project: Confidence intervals for proportions, independent groups
  • IBM SPSS Extension: R Project PowerTOST library

Галерея

20180815 154932
20180815 142325
IMG-20170802-WA0011
DJI 0007
IMG-20170807-WA0002
20180202 161523
  • Anesthetic and Analgesic Drug Products Advisory Committee Roster
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-04-01 By FDA
  • FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Coronavirus (COVID-19) | CBER-Regulated Biologics
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-31 By FDA
  • Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Atovaquone Oral Suspension, USP 750mg/5mL Due to Potential Bacillus Cereus Contamination in the Product
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • We Are Hiring
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Drug Disposal: Questions and Answers
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Human medicines European public assessment report (EPAR): Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron), dinutuximab beta, Neuroblastoma, Date of authorisation: 08/05/2017, Revision: 14, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Guideline on Quality Aspects of Pharmaceutical Veterinary Medicines for administration via drinking water - Draft Annex on compatibility studies between veterinary medicinal products and biocidal products
    Source: EMA - Scientific guidelines (human and veterinary) Published on 2023-03-31
  • Human medicines European public assessment report (EPAR): Dzuveo, sufentanil, Pain, Date of authorisation: 25/06/2018, Revision: 6, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • National Minority Health Month: Better Health Through Better Understanding
    Source: FDA - What's New: Vaccines, Blood & Biologics RSS Feed Published on 2023-03-31 By FDA
  • Human medicines European public assessment report (EPAR): Kisplyx, lenvatinib, Carcinoma, Renal Cell, Date of authorisation: 25/08/2016, Revision: 18, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Identification of Medicinal Products — Implementation and Use
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Newly Added Guidance Documents
    Source: FDA - What's New: Drugs RSS Feed Published on 2023-03-31 By FDA
  • Human medicines European public assessment report (EPAR): Lydisilka, estetrol,drospirenone, Contraceptives, Oral, Date of authorisation: 19/05/2021, Revision: 3, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
  • Human medicines European public assessment report (EPAR): Grasustek, pegfilgrastim, Neutropenia, Date of authorisation: 20/06/2019, Revision: 4, Status: Authorised
    Source: EMA - Human medicines: European public assessment reports (EPARs) Published on 2023-03-31
Older posts
Theme: Scaffold by Danny Cooper.